Trial Profile
An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs Remdesivir (Primary)
- Indications Post acute COVID 19 syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms ERASE-LC
- 20 Dec 2023 Phase of the trial is changed from phase 2 to phase 4.
- 20 Dec 2023 Planned End Date changed from 1 Oct 2025 to 1 Dec 2025.
- 20 Dec 2023 Planned primary completion date changed from 1 Mar 2025 to 1 Oct 2025.